Vanderbilt University Medical Center: New Target For Lung Fibrosis
October 21, 2022
October 21, 2022
NASHVILLE, Tennessee, Oct. 21 (TNSjou) -- Vanderbilt University Medical Center issued the following news:
Idiopathic pulmonary fibrosis (IPF) -- a chronic, progressive syndrome -- is marked by persistent activation and proliferation of fibroblast cells and the pathologic accumulation of extracellular matrix (scar tissue). Most patients die within 3-5 years of diagnosis.
Timothy Blackwell, MD, James West, PhD, and colleagues have now discovered that TBXA2R (thromboxane- . . .
Idiopathic pulmonary fibrosis (IPF) -- a chronic, progressive syndrome -- is marked by persistent activation and proliferation of fibroblast cells and the pathologic accumulation of extracellular matrix (scar tissue). Most patients die within 3-5 years of diagnosis.
Timothy Blackwell, MD, James West, PhD, and colleagues have now discovered that TBXA2R (thromboxane- . . .